Skolkovo, the international tech hub under completion on the outskirt of Moscow, has signed a strategic partnership agreement with the multinational pharmaceuticals giant AstraZeneca to carry out joint scientific research and educational activities in Russia.
The UK-headquartered corporation considers cooperating with Skolkovo startups working in the field of cancer research.
According to the Skolkovo Foundation, the partnership would aim to develop an “innovative mathematical modeling platform that would make it possible to predict the curative potential of combinations of new cancer drugs, as well as to predict the outcome of clinical research being carried out by AstraZeneca in Russia in the field of immuno-oncology.”
The two partners have also agreed on support for educational initiatives aimed at young Russian specialists.
“Being leaders in science is a key priority for AstraZeneca,” said Irina Panarina, general director of AstraZeneca Russia and Eurasia.
“We have been working in Russia for more than a decade, and we strive to make a maximum contribution to the development of local scientific research projects. We’re glad to have a partner like Skolkovo, which fully shares our values and has an innovative way of thinking. I am sure that expanding the sphere of our joint work will open new potential,” she added
In October 2015, AstraZeneca opened a $224 million drug manufacturing and packaging factory in Russia’s Kaluga region, reports the Skolkovo Foundation.
Source: Skolkovo Foundation
